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Abstract
Telomerase reverse transcriptase (TERT) promoter mutations are commonly found in malignant 
melanomas but rare in melanocytic nevi. To assess its potential diagnostic utility for the distinction 
of melanoma from nevus, we determined the TERT promoter mutation status of 86 primary 
melanomas, 72 melanocytic nevi and 40 diagnostically problematic melanocytic proliferations. Of 
the 86 melanomas, 67 (77.9%) were TERT-positive, defined as harboring a hotspot TERT 
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promoter mutation at positions -124C>T, -124_125CC>TT, -138_139CC>TT or -146C>T. Of the 
72 nevi, only one (1.4%) was TERT-positive. Of the 40 diagnostically uncertain melanocytic 
proliferations, two (5.0%) were TERT-positive. TERT-positivity as a test for melanoma versus 
nevus had an accuracy of 87.3% (95% CI, 81.1–92.1), a sensitivity of 77.9% (95% CI, 68.9–85.4), 
a specificity of 98.6% (95% CI, 95.8–100), a positive predictive value of 98.5% (95% CI, 95.6–
100) and a negative predictive value of 78.9% (95% CI, 72.6–85.4). Our results indicate that 
hotspot TERT promoter mutation status may be a useful ancillary parameter for the diagnosis of 
melanoma. In particular, the high specificity of these mutations for melanoma indicates the 
presence of a TERT promoter mutation in a melanocytic neoplasm associated with diagnostic 
controversy or uncertainty should increase concern for a melanoma.
Keywords
melanoma; nevi; TERT promoter mutation; diagnosis; diagnostic biomarkers; telomerase; solar 
elastosis
Introduction
Highly-recurrent somatic C→T mutations in the promoter of the catalytic reverse 
transcriptase subunit of the telomerase (TERT) gene, the ribonucleoprotein complex that 
maintains telomere length, have been reported in up to 67% of primary cutaneous 
melanomas (1–9). The majority are C to T transitions that occur at positions -124 or -146 
upstream from the transcription start site. Mutations at these positions create identical 11-bp 
nucleotide stretches that contain a consensus-binding site for E-twenty-six (ETS) 
transcription factors in the ternary complex factor (TCF) subfamily. Other hotspot TERT 
promoter mutations reported in melanomas that create ETS/TCF binding sites occur at 
positions -57A>C, -124_125CC>TT or -138_139CC>TT from the start site (2, 4, 5, 7, 10). 
Heidenreich et al. found a statistically significant increase in TERT mRNA levels as 
measured by real-time quantitative-polymerase chain reaction (PCR) in melanomas with 
-124C>T, -146C>T, -124_125CC>TT or -138_139CC>TT mutations when compared to 
melanomas without TERT promoter mutations or skin (4). TERT promoter mutations at 
-124C>T and -146C>T increased transcriptional activity in luciferase reporter assays (1, 11). 
Presence of TERT promoter mutation has been associated with worse survival from 
melanoma (8, 12). This effect was modified by a common polymorphism rs2853669 within 
the TERT promoter that disrupts a preexisting non-canonical ETS2 site in the proximal 
region of the TERT promoter immediately adjacent to an E-box (12). Further, TERT 
promoter mutations in spitzoid melanocytic neoplasms were reported to predict aggressive 
clinical behavior (13).
In contrast to malignant melanoma, TERT promoter mutations are rare in melanocytic nevi. 
However, information on TERT promoter status in nevi is limited, since few nevi have been 
examined in this regard (2, 14, 15). Horn et al. screened 25 melanocytic nevi and found only 
one carried a TERT promoter mutation at position -101, which did not create an ETS/TCF 
motif (2). Vinagre et al. did not detect TERT promoter mutations in nine melanocytic nevi 
tested (14). Requena et al. found that none of 15 Spitz/Reed nevi carried TERT promoter 
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mutations; whereas, two of nine atypical spitzoid tumors contained TERT promoter 
mutations, one with a -138_139CC>TT and another a -124C>T alteration (15).
Due to the frequent presence of TERT promoter mutations in cutaneous melanomas but 
rarity in nevi, these mutations may be used as ancillary evidence to support a diagnosis of 
melanoma. To explore their potential diagnostic value for the distinction of nevi from 
melanoma, we analyzed for TERT promoter mutations in a set of primary melanomas, nevi 
and diagnostically problematic melanocytic proliferations.
Methods and Materials
Specimen Selection and Interobserver Review
Formalin fixed, paraffin-embedded specimens were obtained from the University of North 
Carolina (UNC) and University of Rochester (UR) pathology archives based on their 
original diagnosis (cutaneous primary invasive melanoma, nevus or diagnostically uncertain 
melanocytic proliferation) abstracted from pathology reports and diagnosed between 2001 
and 2012. The Institutional Review Boards at UNC and UR approved the study. Melanomas 
were chosen to span 7th edition American Joint Committee on Cancer (AJCC) tumor stages 
(16) and include common and less common histopathological subtypes. Nevi were chosen to 
include a variety of histopathological subtypes. Also, melanocytic tumors of uncertain 
diagnoses were selected, for which pathologists were unsure as to whether they were benign 
or malignant and/or unable to reach a consensus diagnosis. Age, sex, race, anatomic site and 
outcome data were abstracted from the medical record.
A hematoxylin and eosin (H&E)-stained slide of each specimen was initially reviewed by 
one dermatopathologist to assign diagnosis, classify histopathological subtype and score 
standard histopathological features. This reviewer also encircled the melanocytic tissue areas 
on the H&E slides for use as guides in manual microdissection. Two additional 
dermatopathologists reviewed the same series of specimens using H&E-stained slides or 
high-resolution Aperio images and assigned diagnoses of melanoma, nevus or uncertain. For 
the classification of the melanocytic tumors of this study as melanoma or nevus, complete 
consensus between the pathology report and the three dermatopathologist reviewers was 
required for all lesions with event-free follow-up. Incomplete consensus (one pathologist 
may not have been fully certain of the diagnosis) did not exclude a lesion as melanoma if the 
majority of dermatopathologists interpreted the lesion as melanoma and subsequent clinical 
follow-up (visceral metastasis and/or death) provided unequivocal evidence of the 
malignancy of the lesion. Melanocytic proliferations were classified as uncertain if the 
pathologist issuing the original report was not sure whether the lesion was benign or 
malignant or if among the subsequent reviewers at least one dermatopathologist had a 
discordant opinion from the others. After the TERT promoter mutation results were 
available, the one nevus and two uncertain specimens with hotspot TERT promoter 
mutations were examined by two additional dermatopathologists (KJB, PBG) to re-assess 
the prior histopathological classification.
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TERT Promoter Mutation Analysis
Five μm-thick tissue sections were cut from each tissue block and mounted on uncoated 
glass slides. Specimens were manually microdissected using H&E slides as guides and 
DNAs extracted as described (17, 18). Samples were screened for TERT promoter mutation 
by sequencing of a 270-base pair amplicon of the TERT promoter that encompasses the 
main target region for mutations. This region was amplified using M13 tagged primers 
(primer F: 5′-GCCGGGCTCCCAGTGGATTCG; primer R: 5′-
GCTTCCCACGTGCGCAGCAGGAC), as previously described, to amplify from -292 to 
-23 bps from the start site within the promoter region of the TERT gene (19). Several 
melanoma cell lines and tissues had been pre-screened to identify positive and negative 
controls. DNAs were sequenced in the UNC DNA Sequencing Core Facility from the 
purified 270 bp TERT PCR product using cycle sequencing with fluorescently labeled Big 
Dye terminators (Applied Biosystems (ABI), Foster City CA) on an ABI 3730 DNA 
Analyzer. To confirm mutations and eliminate mutational artifacts, we repeated sequencing 
of a separately amplified aliquot of DNA.
Statistical Analysis
TERT-positivity was defined as harboring a hotspot TERT promoter mutation at positions 
-124C>T, -124_125CC>TT, -138_139CC>TT or -146C>T. Diagnostic accuracy was defined 
as the sum of TERT-positive melanoma samples and TERT-negative nevus samples divided 
by total number of all samples. Sensitivity was defined as number of TERT-positive 
melanoma samples (true positive) divided by total number of all melanoma samples (all 
positive). Specificity was defined as number of TERT-negative nevus samples (true negative) 
divided by total number of all nevus samples (all negative). Positive predictive value (PPV) 
was number of TERT-positive melanoma samples (true positive) divided by number of all 
TERT-positive samples (predicted positive). Negative predictive value (NPV) was number of 
TERT-negative nevus samples (true negative) divided by number of all TERT-negative 
samples (predicted negative). Fisher’s exact tests were used to examine associations of 
TERT-positivity with clinicopathologic features. All significance tests were two-sided.
Results
Characteristics of Sample Set
An initial set of 93 melanomas, 80 nevi and 30 diagnostically uncertain melanocytic 
proliferations were selected. After review of these lesions by additional dermatopathologists 
as described above, the diagnoses remained the same for 89 melanomas and 73 benign nevi, 
but 11 lesions designated as nevi (n=7) or melanoma (n=4) on the original pathology report 
were reclassified as uncertain based on lack of consensus. The assigned classification of the 
specimens after interobserver review was 89 melanomas, 73 nevi and 41 uncertain. 
However, three melanomas, one nevus and one uncertain specimen failed TERT promoter 
mutation screening and were excluded from the subsequent analyses. The final sample set 
successfully screened for TERT promoter mutation included 86 melanomas, 72 nevi and 40 
diagnostically uncertain melanocytic proliferations (Table 1).
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The 86 melanomas were from 85 patients; one patient had two synchronous primary 
melanomas, both of which were included in the study. Of the 86 primary melanomas 
screened for TERT promoter mutation, 64.0% were from males, 48.8% from patients 65 
years or older and 89.5% from whites of European origin (Table 1). The melanomas had a 
median Breslow thickness of 1.74 mm (range of 0.37–17.00) and 50% were superficial 
spreading melanomas. Of the 72 nevi, 48.6% were from males, 8.3% from patients 65 years 
or older and 69% from whites of European origin. Of the 40 uncertain specimens, 40% were 
from males, 12.5% from patients 65 years or older and 60% from whites of European origin.
Frequencies of TERT Promoter Mutations
Of the 86 successfully analyzed primary invasive melanomas (Table 2), 67 (77.9%) harbored 
a TERT promoter mutation at one of the known hotspot sites -124C>T, -124_125CC>TT, 
-138_139CC>TT or -146C>T, and these mutations were mutually exclusive of each other. 
Of these, two melanomas with a hotspot mutation also harbored another less common TERT 
promoter mutation creating an ETS/TCF site (-124C>T;-103C>T (n=1) and 
-124C>T;-148C>T (n=1)). Four (4.7%) melanomas without hotspot mutations harbored 
other TERT promoter mutations that create ETS/TCF sites (-103C>T, -105_106CC>TT or 
-148C>T). Also, two melanomas (2.3%) had a TERT promoter mutation that did not form an 
ETS/TCF site (‘non-ETS’ mutation), and thirteen (15.2%) had no TERT promoter mutation. 
Examples of a TERT-positive and a TERT-negative melanoma are illustrated in Figures 1 
and 2, respectively.
Of the 72 nevi, only one intradermal nevus (1.4%) from a 41 year old male, shown in Figure 
3, had a hotspot -124C>T TERT promoter mutation. This patient had the lesion shaved with 
incomplete removal and was alive 64 months after diagnosis without evidence of melanoma. 
After the TERT promoter mutation results were available, this -124C>T TERT-positive 
nevus was examined by two additional dermatopathologists (KJB, PBG) who agreed with 
the diagnosis of nevus. Of the other 71 nevi, seven (9.7%) had a non-ETS mutation and 64 
(88.9%) had no TERT promoter mutations.
Of the 40 diagnostically uncertain specimens, two (5.0%) harbored hotspot TERT promoter 
mutations at -124C>T or -146C>T, one (2.5%) harbored a -156C>T mutation creating an 
ETS/TCF site, two (5.0%) had a non-ETS mutation and 35 (87.5%) had no TERT promoter 
mutation. The uncertain specimen that harbored a TERT promoter mutation at -146C>T is 
illustrated in Figure 4. This specimen was signed out as ‘melanoma but viewed by multiple 
pathologists with differing opinions’. On interobserver review, it was read as melanoma by 
two reviewers and uncertain by one. The patient had 37 months of follow-up with no 
evidence of disease. The other tumor with a hotspot TERT promoter mutation (-124C>T) 
that was placed in this study in the diagnostically uncertain group was signed out with a 
differential diagnosis of atypical compound dysplastic nevus versus thin invasive melanoma. 
On interobserver review, it was interpreted as nevus by two reviewers and classified as 
uncertain by one. Morphologically, it showed a compound melanocytic neoplasm with 
features of a dysplastic nevus and with severe atypia of the intraepidermal component. The 
patient died of causes unrelated to melanoma after 47.4 months of follow-up.
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For determination of diagnostic parameters of TERT-positivity as a test for melanoma versus 
nevus (Table 3), we defined TERT-positive as harboring a hotspot mutation at position 
-124C>T, -124_125CC>TT, -138_139CC>TT or -146C>T. Using this definition, we found a 
diagnostic accuracy of 87.3% (95% CI, 81.1–92.1), a sensitivity of 77.9% (95% CI, 68.9–
85.4), a specificity of 98.6% (95% CI, 95.8–100), a PPV of 98.5% (95% CI, 95.6–100) and a 
NPV of 78.9% (72.6–85.4).
Association with Clinicopathological Features
TERT-positivity in melanomas was associated with age at diagnosis, race, histologic type, 
anatomic site and solar elastosis (all P < 0.05) (Table 4). The frequency of TERT-positivity 
for melanomas was higher for patients age ≥ 65 (90.5%) than those < 65 years (65.9%) and 
for whites of European origin (81.8%) than those of other or unknown race (44.4%). TERT-
positivity was similarly high in superficial spreading (79.1%), nodular (83.3%), lentigo 
maligna (87.5%) and other/unclassified (89.9%) melanomas but acral lentiginous melanoma 
(ALM) had a lower frequency (16.7%). In the other/unclassified category, two nevoid, one 
desmoplastic, one spindle cell melanoma, one spitzoid and three of four unclassified 
melanomas were TERT-positive. For melanoma sites, the frequency was highest for upper 
extremities (100%), followed by the head/neck (85.7%) and then trunk (77.8%) and lowest 
for lower extremities (40.0%). The frequency was higher when solar elastosis was present 
(84.8%) than absent (57.1%). There was no association of TERT-positivity with gender, 
presence of a contiguous nevus, Breslow thickness, ulceration, mitoses, AJCC tumor stage 
and overall stage at diagnosis (8th edition) (20), tumor infiltrating lymphocyte grade, 
regression, histologic pigment or presence of the rs2853669 single nucleotide polymorphism 
in the TERT promoter.
Discussion
We found a diagnostic accuracy of 87.3% (95%, 81.1–92.1) for melanoma versus nevus 
based on TERT-positivity defined as harboring a hotspot TERT promoter mutation. The 
overall sensitivity of TERT-positivity for melanoma was 77.9%, although our data indicate it 
is lower for certain subgroups, including those age < 65 years (65.9%), of other or unknown 
race (44.4%), with lesions on the lower extremity lesions (40%) or without adjacent solar 
elastosis (57.1%) but most clearly for those with ALM (16.7%). Most notably, the specificity 
of TERT-positivity for melanoma versus nevus was 98.6%, with only one of 72 nevi 
harboring a hotspot mutation. Only two of 40 (5%) uncertain specimens were TERT-
positive, indicating that the uncertain group may be enriched with benign nevi. Our data 
cannot fully address which uncertain specimens are melanomas, as 22% of melanomas did 
not harbor hotspot TERT promoter mutations. Nevertheless, because our data indicate that 
TERT-positivity is rare in melanocytic nevi, melanocytic neoplasms with an uncertain 
diagnosis, in which the possibility of melanoma is being seriously considered because of 
worrisome histopathological findings, the detection of hotspot TERT promoter mutations 
should be regarded as evidence that increases the probability that the lesion may in fact be a 
melanoma. Accordingly, a positive test result in a lesion suspected to be a melanoma may 
provide a rationale for surgical management according to melanoma guidelines (21).
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Multiple authors have reported hotspot TERT promoter mutations in melanomas (1–8). 
Although not included in our main analyses for TERT-positivity, we also found in 
melanomas but not nevi a few less common TERT promoter mutations (-103C>T, 
-105_106CC>TT, -148C>T) that form de novo ETS/TCF sites. To our knowledge, these 
mutations have not been studied functionally and only the -105_106CC>TT mutation has 
been previously reported in a melanoma (4). We also found a -156C>T mutation that forms 
an ETS/TCF site in an uncertain specimen and know of a previous report of a -156C>T 
mutation in a cutaneous melanoma (4).
We found TERT-positivity was associated with increased age at diagnosis similar to other 
studies (4, 12, 22, 23). We also found TERT-positivity occurred more frequently in 
melanomas from whites of European ancestry compared to other/unknown races. Notably 
Bai et al. found a low rate of TERT promoter mutations in melanomas in the Asian 
population (24). We found only 16.7% of ALMs harbored TERT promoter mutations. The 
relatively low frequency of TERT promoter mutations in the ALMs is consistent with many 
reports on this issue in the literature (4, 5, 7, 8, 12, 24–26), although a recent report found a 
higher frequency of TERT promoter mutations of 35% (27). Besides promoter mutations, 
TERT activity may also increase in ALMs through TERT copy gains, methylation, or 
translocations (27–29).
Similarly, to Heidenreich et al. (4), we found TERT promoter mutations were associated 
with melanomas arising on sun-exposed anatomic sites (defined as presence of solar 
elastosis in our study). We did not find associations of TERT promoter mutation with 
Breslow thickness, ulceration, tumor stage or mitotic rate, similar to some studies (9, 30) but 
unlike others (4, 7, 8, 12, 23). The differences in results between studies may be influenced 
by the tumor stages examined and sensitivity of the assay utilized for TERT promoter 
mutation detection because, as discussed by Lade-Keller (9), early melanomas may have 
subclonal populations with TERT promoter mutations requiring higher assay sensitivity for 
detection. We found no association of TERT promoter mutation in melanomas with 
regression, unlike studies where negative (31) or positive (32) correlations were reported. 
Unlike Ofner et al. (10) but similar to Nagore et al. (12), we found no significant association 
of TERT promoter mutation with the carrier status of the common single-nucleotide 
polymorphism rs2853669.
To our knowledge, this is the first study to report diagnostic parameters for TERT-positivity 
as a test for melanoma versus nevus and the largest series of nevi investigated to date. 
Inclusion of melanomas of different tumor stages and histologic subtypes and a variety of 
nevus subtypes are strengths of the study. We are not aware of another report in the literature 
or illustration of a relatively banal nevus with a TERT promoter mutation and follow-up. 
Another strength is the interobserver review by several dermatopathologists to classify 
samples. The specimens underwent rigorous TERT promoter mutational analysis with 
inclusion of the less common TERT promoter mutations in the reporting. The inclusion of 
uncertain specimens provides information on whether TERT promoter mutation can be 
found among samples that are difficult to classify.
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Weaknesses of the study include its retrospective design, which can lead to sample selection 
bias. Also predictive values (PPV and NPV) are largely dependent on disease prevalence in 
the examined population, and, thus, may not be transferable to another population (33). We 
included relatively few specimens from non-white patients, and race was missing for some 
specimens. Further, the definition of TERT-positivity affects the diagnostic results and could 
possibly be expanded to include other non-hotspot mutations that formed a de novo 
ETS/TCF site. However, we have insufficient information to consider these non-hotspot 
mutations as diagnostic. Further, we did not consider transcription factor sites disrupted by 
TERT promoter mutations that may be important for melanomagenesis and possibly for 
diagnosis. Last, the assay utilized for TERT promoter mutation detection likely affects the 
diagnostic sensitivity, and each assay utilized will need technical validation.
In conclusion, our results indicate that hotspot TERT promoter mutations may be useful for 
the distinction of melanoma from nevus. From a practical standpoint, we propose that there 
may be a rationale for testing melanocytic tumors with ambiguous features, including 
microscopic findings that raise concern for possible melanoma. The high PPV of TERT-
positivity for melanoma in this sample set (98.5%) indicates that a positive test in a 
melanocytic tumor with worrisome histopathological findings increases the probability that 
the tumor is a melanoma. A positive test, then, may provide evidence for treating the 
melanocytic lesion according to melanoma guidelines (21). However, the NPV of TERT-
positivity for melanoma in our study was 78.9%; thus, lack of TERT positivity in an 
uncertain melanocytic lesion does not rule out melanoma, and, if atypical clinical or 
histopathological findings are present, treatment based on the level of concern should be 
initiated, i.e. judiciously either a conservative excision or treatment as melanoma. To provide 
additional clarity, we do not propose TERT promoter mutation testing for banal-appearing 
nevi or for nevi with unusual features that do not raise concern for possible melanoma. We 
also do not propose TERT promoter mutation testing for histologically unequivocal 
melanomas, as testing would not change the treatment.
However, a greater number of melanocytic lesions must be studied to determine more 
robustly the diagnostic value of the assay. Examination of TERT promoter mutations in 
diagnostically uncertain melanocytic proliferations warrants additional study among patients 
for whom long-term melanoma-specific survival is available, allowing a more objective 
classification and evaluation of the diagnostic and potential prognostic value of a 
melanocytic tumor’s TERT promoter status.
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Superficial spreading malignant melanoma, measuring 1.6 mm in Breslow thickness, 
without ulceration. This melanoma harbored a hotspot -124C>T TERT promoter mutation 
(hematoxylin and eosin; 4.9x magnification).
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Lentigo maligna melanoma, 3.0 mm Breslow thickness, non-ulcerated. No TERT promoter 
mutation was identified (hematoxylin and eosin; 13x magnification).
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A, B Benign, predominantly intradermal melanocytic nevus with a congenital pattern. This 
nevus was found to harbor a hotspot -124C>T TERT promoter mutation. No mitotic figures 
were present (hematoxylin and eosin; 3.8x and 40x magnification, respectively).
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Compound melanocytic neoplasm with severe architectural and cytological atypia. This 
indeterminate case was found to harbor a -124C>T TERT promoter mutation. A. A 
compound melanocytic neoplasm fills and expands the papillary dermis forming a domed 
shaped lesion (hematoxylin and eosin; 31x). B. The junctional component of the tumor has 
discrete nesting of melanocytes without confluence or pagetoid spread of cells (hematoxylin 
and eosin; 200x). C. Areas within the dermal component have expansive groupings of 
epithelioid melanocytes with vesicular chromatin patterns and prominent nucleoli, and there 
are lymphocytes present (hematoxylin and eosin; 200x). D. Mitotic figures (arrow) were 
rarely found in the dermal component of the melanocytic tumor (hematoxylin and eosin; 
400x).
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Table 1
Characteristics of 198 melanocytic specimens analyzed for TERT promoter mutations and classified for 
diagnosis (melanoma, nevus or diagnostically uncertain melanocytic proliferation) after interobserver review
Characteristic
Primary Melanomas (n=86) Nevi (n=72) Uncertain* (n=40)
Number (%) Number (%) Number (%)
Laboratory processing of unstained FFPE tissue sections
 University of North Carolina Pathology Laboratories 81 (94.2) 66 (91.7) 40 (100)
 University of Rochester Pathology Laboratories 5 (5.8) 6 (8.3) –
Sex
 Male 55 (64.0) 35 (48.6) 16 (40.0)
 Female 31 (36.1) 37 (51.4) 24 (60.0)
Age at diagnosis of mole or primary melanoma, yrs
 < 65 44 (51.2) 66 (91.7) 35 (87.5)
 ≥ 65 42 (48.8) 6 (8.3) 5 (12.5)
Race
 Whites of European origin 77 (89.5) 50 (69.4) 24 (60.0)
 Other/unknown 9 (10.5) 22 (30.6) 16 (40.0)
Histologic subtype of primary melanoma
 Superficial spreading 43 (50.0) – –
 Nodular 12 (14.0) – –
 Lentigo maligna 16 (18.6) – –
 Acral lentiginous 6 (7.0) – –
 Other/unclassified† 9 (10.5) – –
Anatomic site of mole or primary melanoma
 Head/neck 28 (32.6) 19 (26.4) 4 (10.0)
 Trunk 27 (31.4) 37 (51.4) 23 (57.5)
 Upper extremities 16 (18.6) 8 (11.1) 2 (5.0)
 Lower extremities 15 (17.4) 8 (11.1) 11 (27.5)
Solar Elastosis adjacent to the melanocytic lesion
 Absent 21 (24.4) 43 (59.7) 34 (85.0)
 Present 59 (68.6) 9 (12.5) 5 (12.5)
 Indeterminate 6 (7.0) 20 (27.8) 1 (2.5)
Contiguous nevus
 Absent 75 (87.2) – –
 Present 11 (12.8) – –
Melanocytic nevus type
 Intradermal – 17 (23.6) –
 Common acquired – 9 (12.5) –
 Congenital pattern – 14 (19.4) –
 Dysplastic – 14 (19.4) –
 Spitz – 9 (12.5) –
 Other‡ – 9 (12.5) –
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Characteristic
Primary Melanomas (n=86) Nevi (n=72) Uncertain* (n=40)
Number (%) Number (%) Number (%)
Breslow thickness of primary melanoma, mm
 Median (range) 1.74 (0.37–17.00) – –
 0.01 to 2.00 45 (52.3) – –
 > 2.00 41 (47.7) – –
Ulceration of primary melanoma
 Absent 52 (60.5) – –
 Present 33 (38.4) – –
 Indeterminate 1 (1.2) – –
Mitoses of primary melanoma
 Absent 17 (19.8) – –
 Present 69 (80.2) – –
AJCC tumor stage at diagnosis (8th edition)
 1a/1b/2a 38 (44.2) – –
 2b/3a/3b/4a/4b 48 (55.8) – –
AJCC overall stage at diagnosis (8th edition)
 IA/IB 34 (39.5) – –
 IIA/IIB/IIC 19 (22.1) – –
 IIIA/IIIB/IIIC 25 (29.1) – –
 IV 3 (3.5) – –
 Unknown 5 (5.8) – –
Tumor infiltrating lymphocyte (TIL) grade
 Absent 20 (23.3) – –
 Present 65 (75.6) – –
 Indeterminate 1 (1.2) – –
Pigment of the melanocytic lesion
 Absent 16 (18.6) 12 (16.7) 7 (17.5)
 Present 70 (81.4) 60 (83.3) 33 (82.5)
Regression
 Absent 70 (81.4) – –
 Present 16 (18.6) – –
*
Melanocytic proliferations were considered diagnostically uncertain if there was interobserver disagreement between any of 3 dermatopathology 
readers or the pathology report diagnosis of nevus vs. melanoma or one of the dermatopathogists or pathology report described the specimen as 
having uncertain diagnosis.
†
Other types of melanoma include nevoid (n=2), desmoplastic (n=1), spindle cell (n=1), spitzoid (n=1) and unclassified (n=4). All of these were 
TERT-positive except two of the unclassified melanomas.
‡
Other includes cellular blue nevus (n=2), combined intradermal or sclerotic blue nevus, not cellular (n=1), combined nevus with compound 
congenital pattern and deep penetrating nevus (n=2), pigmented spindle cell nevus (n=2) and proliferative nodule in congenital pattern nevus (n=2).
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Table 2
TERT promoter mutation status in 86 primary melanomas, 72 nevi, and 40 diagnostically uncertain 
melanocytic proliferations
TERT promoter mutation*
Primary Melanomas (n=86) Nevi (n=72) Uncertain (n=40)
Number (%) Number (%) Number (%)
Hotspot mutations creating ETS/TCF sites† n=67 (77.9%) n=1 (1.4%) n=2 (5.0%)
 -124C>T‡ 29 (33.7) 1 (1.4) 1 (2.5)
 -124_125CC>TT 1 (1.2)
 -138_139CC>TT 4 (4.7)
 -146C>T§ 33 (38.4) 1 (2.5)
Less common mutations creating ETS/TCF sites¶ n=4 (4.7%) n=1 (2.5%)
 -103C>T|| 1 (1.2)
 -105_106CC>TT 1 (1.2)
 -148C>T** 2 (2.3)
 -156C>T†† 1 (2.5)
Mutations not creating an ETS/TCF site n=2 (2.3%) n=7 (9.7%) n=2 (5.0%)
 -85C>T;-154C>T 1 (2.5)
 -106C>T;-117C>T;-149C>T 1 (1.4)
 -107C>T 1 (1.2)
 -116C>T;-179C>T 1 (1.4)
 -125C>T 1 (1.4)
 -149C>T 2 (2.8)
 -149C>T;-127C>T 1 (1.4)
 -149C>T;-160C>T 1 (2.5)
 -151C>T 1 (1.2)
 -161C>T 1 (1.4)
No mutations 13 (15.2) 64 (88.9) 35 (87.5)
*
Bolded mutations create de novo ETS/TCF binding sites.
†
Mutations create confirmed functional ETS/TCF binding sites.
‡
Six melanomas with -124C>T mutations had additional mutations: -124C>T;-101C>T (n=2), -124C>T;-103C>T (n=1), -124C>T;-126C>T (n=1), 
-124C>T;-131C>T;-166C>T (n=1) and -124C>T;-148C>T (n=1).
§
Twelve melanoma with -146C>T mutations had additional mutations: -146C>T;-107C>T;-117C>T (n=1), -146C>T;-149C>T;-153G>A (n=1), 
-146C>T;-165C>G (n=1), -146C>T;-116C>T (n=1), -146C>T;-125C>T (n=2), -146C>T;-126C>T;-195C>A (n=1), -146C>T;-127C>T (n=1), 
-146C>T;-149C>T (n=1), -146C>T;-150C>T (n-1), -146C>T;-150C>T;-166C>T (n=1) and -146C>T;-101C>T;-165C>T (n=1).
¶
Mutations create ETS/TCF sites but less common and not confirmed to be functional.
||
The melanoma with the -103C>T mutation also had a -160C>T mutation.
**
One of the melanomas with a -148C>T mutation also had the following mutations: -161C>T;-175C>T;-187C>T;-242C>T
††
The uncertain sample with the -156C>T mutation also had a -149C>T mutation.
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Table 4
Relationship of TERT-positivity to clinicopathologic features in primary melanomas (n = 86)*
Clinicopathologic Feature
TERT-negative (n=19) TERT-positive (n=67)
P-value†Number (%) Number (%)
Sex
 Male 13 (23.6) 42 (76.4) 0.79
 Female 6 (19.4) 25 (80.7)
Age, years
 < 65 15 (34.1) 29 (65.9) 0.005
 ≥ 65 4 (9.5) 38 (90.5)
Race
 Whites of European origin 14 (18.2) 63 (81.8) 0.02
 Other/Unknown 5 (55.6) 4 (44.4)
Histologic subtype
 Superficial Spreading 9 (20.9) 34 (79.1) 0.01
 Nodular 2 (16.7) 10 (83.3)
 Lentigo maligna 2 (12.5) 14 (87.5)
 Acral lentiginous 5 (83.3) 1 (16.7)
 Other/unclassified‡ 1 (11.1) 8 (89.9)
Site
 Head/neck 4 (14.3) 24 (85.7) <.001
 Trunk 6 (22.2) 21 (77.8)
 Upper extremities 0 16 (100.0)
 Lower extremities 9 (60.0) 6 (40.0)
Solar elastosis
 Absent 9 (42.9) 12 (57.1) 0.03
 Present 9 (15.3) 50 (84.8)
 Indeterminant 1 (16.7) 5 (83.3)
Contiguous nevus
 Absent 17 (22.7) 58 (77.3) 1.00
 Present 2 (18.2) 9 (81.8)
Breslow thickness (mm)
 0.01 to 2.00 8 (17.8) 37 (82.2) 0.44
 > 2.00 11 (26.8) 30 (73.2)
Ulceration
 Absent 12 (23.1) 40 (76.9) 0.85
 Present 7 (21.2) 26 (78.8)
 Indeterminant 0 1 (100.0)
Mitoses
 Absent 3 (17.7) 14 (82.4) 0.75
 Present 16 (23.2) 53 (76.8)
AJCC tumor stage at diagnosis (8th edition)
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Clinicopathologic Feature
TERT-negative (n=19) TERT-positive (n=67)
P-value†Number (%) Number (%)
 T1a/T1b/T2a 7 (18.4) 31 (81.6) 0.60
 T2b/T3a/T3b/T4a/T4b 12 (25.0) 36 (75.0)
AJCC overall stage at diagnosis (8th edition)
 IA/IB 5 (14.7) 29 (85.3) 0.48
 IIA/IIB/IIC 5 (26.3) 14 (73.7)
 IIIA/IIIB/IIIC 6 (24.0) 19 (76.0)
 IV 1 (33.3) 2 (66.7)
 Unknown 2 (40.0) 3 (60.0)
Tumor infiltrating lymphocyte grade
 Absent 5 (25.0) 15 (75.0) 0.82
 Present 14 (21.5) 51 (78.5)
 Indeterminant 0 1 (100)
Pigment
 Absent 3 (18.8) 13 (81.3) 1.00
 Present 16 (22.9) 54 (77.1)
Regression
 Absent 18 (25.7) 52 (74.3) 0.11
 Present 1 (6.3) 15 (93.8)
rs2853669
 Absent 10 (20.4) 39 (79.6) 0.50
 Present 8 (22.9) 27 (77.1)
 Indeterminant 1 (50) 1 (50)
Definitions: AJCC, American Joint Committee on Cancer
*
TERT-positivity is defined as harboring a hotspot TERT promoter mutation: -124C>T, -124_125CC>TT, -138_139CC>TT or -146C>T.
†
P-values were derived from the Fisher’s exact test. Bold type indicates P-values < .05 (two-sided).
‡
Other/unclassified types of melanoma include nevoid (n=2), desmoplastic (n=1), spindle cell (n=1), spitzoid (n=1) and unclassified (n=4).
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